Most cellular interaction partners involved in HBV capsid trafficking—such as importins, dyneins, protein kinases, and nuclear pore proteins—are essential for cell viability, making them challenging therapeutic targets due to the high likelihood of significant side effects, as evidenced by anti-cancer drugs that target these proteins. The gene discussed is WEE1; the disease is cancer.